The initiation of coverage by Capital One with an Overweight rating and a specific price target of $6 suggests a positive outlook on Heron Therapeutics' stock. This analyst rating can influence investor sentiment and potentially lead to a short-term increase in the stock price, as it may be perceived as a credible endorsement of the company's value and future prospects.